ArticleJournal of analytical toxicology2026
Paper spray mass spectrometry for rapid toxicology targeted screening of emergency department samples: a research study.
Article in Journal of analytical toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute recreational drug toxicity (ARDT) is a frequent cause of emergency department (ED) presentations, yet comprehensive toxicological testing by chromatographic techniques is rarely conducted due to limited availability and resource-intensive workflows. Consequently, initial clinical decisions are made without analytical confirmation. Paper spray-mass spectrometry (PS-MS) may offer an alternative approach for targeted clinical toxicology screening owing to its rapid and simplified analysis of biological samples. Serum donor samples from patients presenting to the ED with suspected ARDT were analyzed using PS-MS and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for method comparison. Targeted screening and quantitative performance were evaluated using pooled diagnostic metrics, orthogonal regression, per-analyte % bias and Bland-Altman analyses. PS-MS was subsequently applied to a larger screening-only cohort to assess analytical performance, detection frequency, and concentration distributions across a clinically relevant drug panel. Across 114 research samples, PS-MS demonstrated high targeted screening performance, with a pooled sensitivity of 82.7%, specificity and positive predictive value of 100%, and negative predictive value of 98.2%. Quantitative comparison showed strong correlation between methods, with proportional bias at higher concentrations and no single analyte influencing the agreement metrics. In the screening-only cohort (n = 99), PS-MS detected and quantified a broad range of analytes, including evidence of polydrug use. Several low-frequency analytes were not observed within the analyzed serum donor sample cohort. PS-MS may provide a fast and specific targeted screening approach for ARDT in ED samples, delivering analytically informative toxicological data. While not a replacement for confirmatory testing or a validated in vitro diagnostic assay, this research study into PS-MS represents a valuable complementary tool to support downstream confirmatory testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.